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ABSTRACT Trypanosoma cruzi is the etiologic agent of Chagas disease, and current methods for its genetic manipulation have
been highly inefficient. We report here the use of the CRISPR (clustered regularly interspaced short palindromic repeats)/Cas9
(CRISPR-associated gene 9) system for disrupting genes in the parasite by three different strategies. The utility of the method
was established by silencing genes encoding the GP72 protein, which is required for flagellar attachment, and paraflagellar rod
proteins 1 and 2 (PFR1, PFR2), key components of the parasite flagellum.We used either vectors containing single guide RNA
(sgRNA) and Cas9, separately or together, or one vector containing sgRNA and Cas9 plus donor DNA for homologous recombi-
nation to rapidly generate mutant cell lines in which the PFR1, PFR2, andGP72 genes have been disrupted. We demonstrate that
genome editing of these endogenous genes in T. cruzi is successful without detectable toxicity of Cas9. Our results indicate that
PFR1, PFR2, and GP72 contribute to flagellar attachment to the cell body andmotility of the parasites. Therefore, CRISPR/Cas9
allows efficient gene disruption in an almost genetically intractable parasite and suggest that this method will improve the func-
tional analyses of its genome.
IMPORTANCE Trypanosoma cruzi is the agent of Chagas disease, which affects millions of people worldwide. Vaccines to prevent
this disease are not available, and drug treatments are not completely effective. The study of the biology of this parasite through
genetic approaches will make possible the development of new preventive or treatment options. Previous attempts to use the
CRISPR/Cas9 in T. cruzi found a detectable but low frequency of Cas9-facilitated homologous recombination and fluorescent
marker swap between exogenous genes, while Cas9 was toxic to the cells. In this report, we describe new approaches that gener-
ate complete disruption of an endogenous gene without toxicity to the parasites and establish the relevance of several proteins
for flagellar attachment andmotility.
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Trypanosoma cruzi is the etiologic agent of Chagas disease inhumans. Millions of people are affected by this trypanosomi-
asis in North, Central, and South America, where the disease is
endemic, as well as in countries where the disease is not endemic,
where it occurs mostly in migrant workers or blood transfusion
and organ transplant recipients. No vaccines are available to pre-
vent this disease, and drug treatments have serious side effects or
are not completely effective (1). The study of the biology of this
eukaryotic organism will make possible the development of spe-
cific inhibitors as possiblemeans of controlling the parasites with-
out damaging the hosts.
Few cellular and genetic tools are available toworkwithT. cruzi
(2, 3). The parasite is predominantly diploid, and thus, inactiva-
tion of most genes requires two rounds of gene replacement.
However, attempts to generate null mutants by homologous re-
combination sometimes yield parasites bearing the two planned
replacements but also bearing extra copies of the genes through
aneuploidy or gene amplification (4, 5). The RNA interference
(RNAi) technique for gene knockdowns has been well developed
inTrypanosoma brucei, which belongs to the group of agents caus-
ing African trypanosomiasis, but the RNAi machinery is absent
fromT. cruzi (2, 6). Some recent genetic tools toworkwithT. cruzi
include the development of stable tetracycline-regulated expres-
sion vectors (7), which are not always successful with membrane
proteins, and new cloning systems for reverse genetics based on
the gateway technology (8, 9), but the field is considerably behind
what it is possible to do in comparison with T. brucei (2). Cur-
rently, the most efficient genetic tool available in T. cruzi is the
overexpression of genes with the pTREX vector (10), a system that
allows constitutive gene expression driven by the promoter of ri-
bosomal genes, as well as sequence integration into the ribosomal
DNA locus. This strategy has been used to upregulate gene expres-
sion in T. cruzi (11–13), but downregulation of genes in this or-
ganism still remains inefficient. In contrast to other trypano-
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somes, T. cruzi epimastigotes have a long generation time and
amastigotes require a host cell to grow. Only a few trypomastig-
otes are enough to infect humans and laboratory accidents are also
a concern (14, 15). The consequence of all of these problems is that
these organisms are not very amenable to genetic or cellular anal-
yses, while they possess a number of characteristics that cannot be
studied in other models.
One of the peculiarities of kinetoplastida, shared with Eu-
glenida, is the presence of the paraflagellar rod (PFR), a complex,
trilaminar, lattice-like structure linked to the axonemal microtu-
bules of the flagellum (16). Two core components of the PFR are
PFR protein 1 (PFR1) and PFR2, which in T. cruzi correspond to
what was known as PAR3 and PAR2 (17), respectively. The genes
encoding PFR1 and PFR2 are distinct but related and are present
in separate tandem arrays in T. brucei (16). Disruption of these
genes has been used to test different RNAi approaches in both
T. brucei (18) and Leishmania braziliensis (19). While disruption
of these genes results in viable procyclic forms (PCF) of T. brucei
(18, 20, 21) or Leishmania sp. promastigotes (18, 22, 23), disrup-
tion in bloodstream forms (BSF) of T. brucei is lethal (21). T. bru-
cei PCF RNAi mutants (21) and Leishmania mexicana null mu-
tants (22) for PFR2 show a dramatic decrease in flagellar motility
and changes in morphology, while some authors were unable to
obtain double-knockout PCF trypanosomes (24). A “blob” of ac-
cumulated PFR components is also detected at the tip of the fla-
gellum of PCF RNAi mutants, but the flagellum remains attached
to the cell body (21). Another peculiar protein of trypanosomes is
an immunodominant glycoprotein localized to the junction be-
tween the flagellum and the cell body that is named GP72 in
T. cruzi (25–28) or FLA1 in T. brucei (29) and is essential for
flagellar attachment in both T. cruzi (28) and T. brucei (29).
The advent of the prokaryotic CRISPR (clustered regularly in-
terspaced short palindromic repeats)/Cas9 (CRISPR-associated
gene 9) system has been transformative in biology and has been
used for genome editing in diverse organisms, ranging from yeast
to mammals and including pathogenic protozoa (30–33). While
our work was in preparation, an attempt to use it in T. cruzi was
reported (34). The authors used in vitro-transcribed single guide
RNA (sgRNA) to transfect cells and target a previously transfected
exogenous gene (that for green fluorescent protein [GFP]) or
single- and multiple-copy endogenous genes and found a detect-
able but low frequency of Cas9-facilitated homologous recombi-
nation and fluorescent marker swap between exogenous genes
(GFP and tdTomato) (0.11 and 0.069% rates of fluorescent
marker swap) (34). Cas9 expressionwas, in addition, toxic to these
cells (34).
In this report, we demonstrate by three different strategies (us-
ing pTREX vectors containing sgRNA and Cas9, separately or to-
gether, or one pTREX vector containing sgRNA and Cas9 plus a
donorDNA for homologous recombination) that genome editing
of endogenous genes in T. cruzi is successful with no detectable
toxicity of Cas9. Our results also indicate that PFR1, PFR2, and
GP72 are all required for flagellar attachment to the cell body of
the epimastigote stages ofT. cruzi, demonstrating the utility of the
CRISPR/Cas9 system in elucidating the role of specific genes in
this organism.
RESULTS
To investigate whether the CRISPR/Cas9 system could be used to
silence genes of T. cruzi, we used a genetically modified version of
the type II CRISPR system from Streptococcus pyogenes, consisting
of the endonuclease Cas9 and an engineered RNA chimera or
sgRNA that conform a ribonucleoprotein complex able to recog-
nize the target sequence and produce double-strand breaks (35).
Double-strand breaks generated by Cas9 can be repaired by ho-
mologous recombination with donor DNA or by error-prone,
nonhomologous end joining (NHEJ) (35). Trypanosomatids are
deficient in canonical NHEJ, but they have a more recently char-
acterized repair mechanism, named microhomology-mediated
end joining (MMEJ) (36–38). MMEJ repairs DNA breaks via the
use of substantial microhomology and always results in deletions
(39, 40).
The constructs used in this study are shown in Fig. 1. We first
investigated whether it was possible to target Cas9 to the nucleus
of T. cruzi by using an exogenous nuclear localization signal. We
transfected epimastigotes with either Cas9/pTREX-n or Cas9/
pTREX-b (Fig. 1A) vector containing the S. pyogenes Cas9 se-
quence with a twice-repeated sequence of the simian virus 40
(SV40) nuclear localization signal (2NLS) and GFP or with the
empty vector (pTREX-b or pTREX-n). GFP expression was mon-
itored to determine the transfection efficiency, revealing that
~20% of cells showed colocalization of GFP with 4=,6-diamidino-
2-phenylindole (DAPI)-staining nuclei. Figure S1A in the supple-
mental material shows the results obtained with the Cas9/p-
TREX-b vector after increasing the percentage of fluorescent cells
by fluorescence-activated cell sorting (FACS). These cells exhibit
green fluorescent nuclei, as observed by colocalizationwithDAPI,
confirming the nuclear localization of the fusion endonuclease
Cas9-GFP. Similar results were obtained with the Cas9/pTREX-n
vector. Cells transfected with the empty vectors showed normal
morphology and flagellar staining with antibodies against T. cruzi
flagellar calcium binding protein (TcFCaBP) (see Fig. S1B in the
supplemental material). Recombinant plasmids Cas9/pTREX-n
and Cas9/pTREX-b were then used to develop two different ap-
proaches for gene silencing involving the transfection of epimas-
tigotes with one (CRISPR-1V, Fig. 1B) or two (CRISPR-2V,
Fig. 1C) vectors, respectively.
We initially chose TcPFR1 and TcPFR2 for gene silencing be-
cause their orthologs have been used before as knockdown targets
inT. brucei andL. braziliensis to evaluate the efficiency of theRNAi
system in these organisms, producing a nonlethal butmorpholog-
ically easy-to-characterize phenotype (20, 41, 42). We also chose
TcGP72 because knockout of this gene results in flagellar detach-
ment without loss of viability (28). The sgRNA sequences used to
target these genes contained a 20 (TcGP72)- or 25 (TcPFR1 and
TcPFR2)-nucleotide (nt) region that targeted a complementary
sequence (the protospacer) immediately upstream of a
protospacer-adjacentmotif (PAM, anNGG sequence required for
S. pyogenesCas9 recognition) (35). To ensure target specificity, we
compared the protospacers to the T. cruzi genome to identify ho-
mologous sequences that contained both the protospacers and a
PAM, and we were not able to identify any sequence with fewer
than sixmismatcheswith the ProtoMatch v1.0 script (31).We also
transfected cells with a vector containing a scrambled sgRNA
(pTREX-s) where the protospacer was replacedwith a sequence of
20 scrambled nucleotides that do not target any gene on the
T. cruzi genome.
For the CRISPR-1V strategy (one single vector for expression
of sgRNA and Cas9), we took advantage of the fact that transcrip-
tion in trypanosomatids is polycistronic. Therefore, we arranged
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FIG 1 Restriction map of molecular constructs generated for the CRISPR/Cas9 system in T. cruzi. (A) Cas9/pTREX-n and Cas9/pTREX-b are two plasmids
derived from vectors pTREX-n and pTREX-b (10), respectively, by insertion of the Cas9-HA-2NLS-GFP fusion gene through XbaI and HindIII restriction
sites. (B) CRISPR-1V strategy: plasmids sgRNA/Cas9/pTREX-n and sgRNA/Cas9/pTREX-b were derived from the plasmids in panel A by insertion of a specific
sgRNA fragment through the BamHI site. These plasmids differ only in the resistance gene (neomycin or blasticidin), and they allow the expression of a specific
sgRNA together with Cas9 through a single transfection event of wild-type epimastigotes. (C) CRISPR-2V strategy. A specific sgRNA and the fusion gene
Cas9-HA-2NLS-GFP were individually cloned into two different plasmids to generate sgRNA/tdTomato/pTREX-b and Cas9/pTREX-n (the same as in panel
A) for sequential transfection and coexpression of Cas9 and sgRNA in T. cruzi epimastigotes. In this strategy, sgRNA/tdTomato/pTREX-b (conferring cytoplas-
mic red fluorescence and blasticidin resistance) was used to transfect T. cruzi epimastigotes expressing Cas9 (green fluorescent and neomycin resistant) to
generate CRISPR-ablated, red/green fluorescent parasites. Rib. Prom, ribosomal promoter; AmpR, ampicillin resistance gene; Neo, neomycin resistance gene;
Bsd, blasticidin-S deaminase gene. HX1 and gapdh are trans-splicing regions described in reference 10. Cas9-HA-2NLS-GFP is a fusion gene described in
Materials and Methods. tdTomato encodes a red fluorescent tag protein. sgRNA is a fragment containing the sequence of a chimera sgRNA that, together with
Cas9, targets a specific gene.
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the sequences of a specific sgRNA (or scrambled sgRNA) andCas9
upstream and downstream of the HX1 trans-splicing signal in the
pTREXvector (10), respectively (Fig. 1B). In this way, we obtained
a construct to generate the CRISPR/Cas9 ribonucleoprotein com-
plex in T. cruzi by using a one-step transfection protocol. The
construct (sgRNA/Cas9/pTREX) allowed the transcription of
both sequences (the sgRNAand theCas9 gene) and the translation
and nuclear import of Cas9 alone (Cas9-HA-2NLS-GFP). The
TcPFR1 andTcPFR2 sgRNAs were cloned into the Cas9/pTREX-b
vector to generate the TcPFR1sgRNA/Cas9/pTREX-b and
TcPFR2sgRNA/Cas9/pTREX-b constructs (blasticidin resistant),
while the TcGP72 sgRNAwas cloned into the Cas9/pTREX-n vec-
tor to generate the TcGP72sgRNA/Cas9/pTREX-n plasmid (neo-
mycin resistant). These plasmids were then used to transfect epi-
mastigotes and generate green fluorescent mutant cell lines. After
selection in the presence of blasticidin or neomycin, respectively,
cell sorting was done to enrich the populations of GFP-expressing
parasites (CRISPR-1V strategy). Control growth curves of para-
sites transfected with the scrambled sgRNA andCas9 were normal
after a short lag period, suggesting lack of toxic effects of Cas9 or
the scrambled sgRNA (see Fig. S1C in the supplemental material).
Figure 2A shows the presence of parasites with different de-
grees of flagellar detachment in the cells with PFR2 disrupted
(Fig. 2A,white arrows). Figure 2B shows the complete detachment
of the flagellum from the cell body in a PFR2-disrupted epimas-
tigote. Alternatively, the TcPFR1 and TcPFR2 genes were dis-
rupted by CRISPR by using a two-vector strategy (CRISPR-2V) to
generate double-resistant (neomycin/blasticidin) red/green fluo-
rescent cell lines. Phenotypic changes were similar to those ob-
tained by the CRISPR-1V approach, thus confirming that TcPFR1
and TcPFR2 disruption results in flagellar detachment to the epi-
mastigote cell body. Figure 2C shows different degrees of flagellar
detachment in a population of PFR1-disrupted epimastigotes by
the CRISPR-2V strategy (Fig. 2C, white arrows). Note the pres-
ence of a green nucleus and red cytoplasm in these cells (Fig. 2C
and D). Not all epimastigotes showed flagellar detachment at any
given time, and growing numbers of isolated flagella were ob-
served in the culturemedium (see Fig. S2A to C in the supplemen-
tal material). Epimastigote-like cells devoid of flagella (see
Fig. S2D to F in the supplemental material) were also observed in
these populations. The gradual development of the phenotypic
changes was also revealed by the presence of blobs at the tip or
close to the tip of the flagella, after staining with anti-FCaBP an-
tibodies (see Fig. S3 in the supplemental material).
Examination of TcPFR1 and TcPFR2 CRISPR-disrupted epi-
mastigotes demonstrated the lack of the paraflagellar rod in these
mutants, as visualized by electron microscopy (EM) in longitudi-
nal and cross sections (Fig. 3A). Western blot analysis confirmed
FIG 2 Fluorescence microscopy of TcPFR1 and TcPFR2 CRISPR-ablated epimastigotes. (A and B) The TcPRF2 gene in T. cruzi epimastigotes was disrupted by
the CRISPR-1V strategy. Detached flagella are indicated by white arrows in the differential interference contrast (DIC) image in panel A, and the detail of a single
cell is shown in panel B. Cas9-GFP fusion protein (green) colocalizes with DAPI-stained nuclei (blue). Antibodies against flagellar calcium-binding protein
(FCaBP) were used to label flagella (red). (C and D) The TcPRF1 gene in T. cruzi epimastigotes was disrupted by the CRISPR-2V strategy. Detached flagella are
indicated by white arrows in the DIC image in panel C, and a single-cell detail is shown in panel D. Cas9-GFP fusion protein (green) colocalizes with
DAPI-stained nuclei (yellow). TdTomato expression (red) is cytosolic. Merged images are shown on the right side of each panel. Bars 10 m.
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the decreased labeling of both PFR1 (7 to 39% of the expression in
wild-type cells) and PFR2 (0 to 56% of the expression in wild-type
cells) when any one of the genes was disrupted by either the
CRISPR-1V or the CRISPR-2V strategy (Fig. 3B), suggesting that
lack of either protein prevents the complete assembly of the para-
flagellar rod. Detailed examination by scanning EM also revealed
flagellar detachment from the cell body (see Fig. S4B and C in the
supplemental material).
As reported before in a knockout mutant (27), disruption of
TcGP72 by CRISPR/Cas9 also resulted in flagellar detachment
(compare Fig. 4A and B). While the glycan epitope recognized by
monoclonal antibody (MAb) WIC29.26 (43) was evenly distrib-
uted over the entire surface of the epimastigote, including the
flagellum (Fig. 4A), very little staining remained in the detached
flagella of mutant epimastigotes (Fig. 4B). The abnormal flagellar
attachment affected the motility of these epimastigotes, which
tended to sink faster than the wild-type epimastigotes. Western
blot analysis of TcGP72 mutants with MAb WIC29.26 showed a
significant decrease in the labeling of the 72-kDa band compared
to that in wild-type epimastigotes (Fig. 4C). As reported before
(28), this antibody recognizes the glycan epitope in additional
lower- and higher-molecular-weight proteins (Fig. 4C). Trans-
mission EM (TEM) examination of thewild type (Fig. 4D) and the
TcGP72 CRISPR mutant (Fig. 4E) revealed the flagellar detach-
ment with preservation of the paraflagellar rod and no othermor-
phological changes, as reported for the GP72 knockout mutants
(28). Flagellar detachment was also evident on examination by
scanning EM (see Fig. S4D in the supplemental material).
After obtainingmutant-enrichedmixed populations by FACS,
clonal populations of epimastigotes with TcPFR2 disrupted were
obtained by serial dilutions in 96-well plates as described in Ma-
terials and Methods. To investigate the mutations caused by
CRISPR/Cas9, we amplified a portion of the TcPFR2 genomic
locus with primers flanking the Cas9-targeted sequence. The am-
plified loci were cloned, and individual clones were sequenced.
Initially, we used primers to amplify 200- and 500-bp fragments,
but after several attempts to find mutations, we designed primers
to amplify longer regions (1 and 1.5 kb) where the protospacer of
TcPFR2 was approximately in the middle of the sequence. How-
ever, after analyzingmore than 100 clones, we were unable to find
deletions. Northern blot analyses showed a marked decrease in
mRNA expression in several of the clones analyzed (Fig. 5A and
B). To rule out the simultaneous downregulation of genes located
in the same polycistron, we also performedNorthern blot analyses
of genes situated upstream (trafficking protein particle complex
subunit 3,TcPPCS3) and downstream (DNA polymerase catalytic
subunit, TcDPaCS) of the TcPFR2 gene, but there was no down-
regulation of the expression of these genes (Fig. 5C). However,
Southern blot analysis of some of these clones revealed dramatic
changes suggesting large deletions ofTcPFR2 (Fig. 5D). The use of
EcoRI digestion of genomic DNA (gDNA) was based on the
T. cruzi Esmeraldo-like genomic sequence that would generate a
unique band of 4,658 bp in wild-type parasites. However, the pat-
tern obtained was different from that expected. As the Y strain
genome sequence is not yet available, we are unable to predict the
labeling pattern generated with any restriction enzyme/probe
used. However, this result is strong evidence of genome editing in
PFR2 CRISPR mutants.
Since these experiments failed to demonstratemutations in the
targeted endogenous genes, we investigated whether the CRISPR/
Cas9 system could be used to facilitate gene knockout by integra-
tion of a selectable marker (CRISPR/HR strategy). We cotrans-
fected the TcPFR2sgRNA/Cas9/pTREX-n plasmid with a donor
DNA fragment consisting of a linear cassette with the blasticidin
resistance gene (Bsd) flanked by homology arms corresponding to
100-bp regions upstream of the start codon and downstream of
the Cas9 target site in the TcPFR2 gene. Following cotransfection,
epimastigoteswere selectedwith neomycin andblasticidin and the
FIG 3 TEM and Western blot analysis of TcPFR1 and TcPFR2 CRISPR-
ablated epimastigotes. (A) T. cruzi epimastigotes withmutant PFR1 (CRISPR-
1V) and PFR2 (CRISPR-2V) were fixed, stained, and subjected to TEM. The
localization of the paraflagellar rod (P) adjacent to the flagellar axonemes (F)
was observed in wild-type (WT) cells, while it was absent from mutant para-
sites (PFR1 and PFR2), as shown in cross sections (top images) and longitudi-
nal sections of the flagellum (bottom images). Scale bars: 200 nm. (B)Western
blot analysis of control and CRISPR-ablated epimastigotes. Total lysates
(20 g/lane) of wild-type (WT) epimastigotes, control parasites transfected
with plasmids pTREX-b (pTREX) andCas9/pTREX-n (Cas9), andmutant cell
lines producing PFR1 and PFR2 (CRISPR-1V and -2V) were analyzed by
Western blot analysis with MAb L13D16 (44), which recognizes the PFR1 and
PFR2proteins (73 and 69 kDa, respectively). The same blotwas incubatedwith
anti-GFP and anti--tubulin antibodies (loading control). Cell lines are indi-
cated above the blot, and antibodies are shown on the right.
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stable double-resistant cells were subjected to PCR and Western
blot analyses. Disruption of the TcPFR2 gene was verified by PCR
with primers annealing outside the homology regions on the blas-
ticidin cassette (primers 13 and 14; see Table S1 in the supplemen-
tal material), to amplify a fragment from nt 142 to nt 234 of
the TcPFR2 locus (Fig. 6A). A fragment of 696 bp was amplified
from gDNA isolated from a TcPFR2 knockout (TcPFR2-KO)mu-
tant obtained by CRISPR/Cas9 by the donor DNA strategy
(Fig. 6B, lane 5), indicating disruption of the PFR2 gene, which
generates a fragment of 376 bp in the original locus (Fig. 6B, lanes
1 to 4). Western blot analysis with MAb L13D16 (44), which rec-
ognizes the TcPFR1 and TcPFR2 proteins (73 and 69 kDa, respec-
tively), showed the absence of TcPFR2-encoded protein in this
mutant cell line (Fig. 6C). This result confirmed our previous
observation of a significant decrease in the level of TcPFR1 protein
accompanying the disappearance of TcPFR2, which we attribute
to the role of TcPFR2 in the assembly of the paraflagellar rod
structure. Finally, flagellar detachmentwas observed in 86%of the
cells by light microscopy (Fig. 6D) without significant changes in
cell growth (Fig. 6E). Cells that did not exhibit flagellar detach-
ment showed abnormally thin flagella, while a loss of forward cell
motility was observed in the entire population. This motility de-
fect was compatible with the cell sinking phenotype observed for
this mutant in culture flasks. Taken together, our results indicate
that the CRISPR/Cas9 system allowed efficient genome editing in
T. cruzi, and the cotransfection of epimastigotes with a linear cas-
sette for homology recombination improved the editing efficiency
by generating a mutant cell line where the entire population ex-
hibits gene disruption and ablation of the TcPFR2 protein in-
volved in paraflagellar rod assembly, flagellar attachment, and cell
motility.
DISCUSSION
T. cruzi has been especially refractory to genetic manipulation,
and the implementation of the CRISPR/Cas9 technology in this
organism will greatly facilitate the functional analysis of its ge-
nome. Here we report the use of separate or single plasmids con-
taining sgRNA and Cas9 to promote rapid and efficient editing of
T. cruzi genomic loci. In addition, CRISPR/Cas9 provided a very
efficient system for site-specific insertion of a selectable marker
through homologous recombination and resulted in 100% dis-
ruption of an endogenous gene. In previous work (34), Cas9-
facilitated homologous recombination in T. cruzi was only tested
by swapping one exogenous gene (that for GFP) with another
(that for tdTomato). However, this method yielded only 0.11 and
0.069% rates of fluorescent marker swapping. CRISPR/Cas9-
mediated homologous recombination was also used recently in
Leishmania major to replace PFR2 genes with a puromycin resis-
FIG 4 Phenotype of TcGP72 CRISPR-ablated epimastigotes. Fluorescence microscopy of wild-type epimastigotes (A) and epimastigotes with TcGP72 ablated
by the CRISPR-1V strategy (B). Cas9-GFP fusion protein (green) colocalizes with DAPI-stained nuclei (blue). MAbWIC29.26 was used to label TcGP72 in the
cells (red). A detached flagellum is indicated by a white arrow in the DIC image. Bars  10 m. (C) Western blot analysis of control and CRISPR-ablated
epimastigotes. Total lysates (20 g/lane) of wild-type (WT) epimastigotes and epimastigotes with TcGP72 ablated were analyzed by Western blot with MAb
WIC29.26, which recognizes GP72 and other glycoproteins. There is a significant decrease in labeling of TcGP72 (arrowhead) but not of other proteins. The same
blot was incubated with anti--tubulin antibodies (loading control). Molecular masses of markers are indicated at the left. Transmission electron micrographs
of wild-type epimastigotes (D) and epimastigotes with TcGP72 ablated by CRISPR (E) showing the preservation of the paraflagellar rod (PFR) and detached
flagellum in the mutant cell. Ac, acidocalcisomes; K, kinetoplast; N, nucleus. Bars: 0.5 m.
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tance cassette (23). However, in that work, mixed cell populations
were obtained, suggesting that genome editing was not 100% ef-
ficient. In contrast, our homologous recombination method re-
sulted in a clean site-specific disruption of TcPFR2, as detected by
PCR and Western blot analyses. Moreover, this mutant cell line
was obtained fromaunique transfection eventwithout the need to
select clonal populations, which is usually time consuming.While
previous work with kinetoplastids required cotransfection of cells
with in vitro-transcribed sgRNA and two plasmids (34) or
cotransfection with three plasmids (23) to induce CRISPR/Cas9-
facilitated homologous recombination, we achieved highly effi-
cient genome editing by using a single plasmid (sgRNA/Cas9/
pTREX-n), cotransfecting it with a PCR-amplified blasticidin
cassette for homologous recombination.Wewere able to generate
this mutant cell line after exactly 5 weeks of selection, a goal that
was not previously achieved with T. cruzi. The high efficiency ob-
served with this system is possibly a consequence of the constitu-
tive expression of Cas9 and the sgRNA cloned together into the
pTREX-n vector, which permanently produces a site-directed
double-strand DNA break that is further repaired by homologous
recombination with the blasticidin homology template.When the
selectablemarker is inserted into at least one allele of the gene, this
allele works as the template to repair any other Cas9-induced
break occurring in the second allele, or in other gene copies pos-
sibly present, by a mechanism similar to the mutagenic chain re-
action recently described (45). A schematic representation of the
strategies developed for CRISPR/Cas9-mediated genome editing
in T. cruzi is shown in Fig. S5 in the supplemental material.
Expression of sgRNAandCas9 alone (one- or two-vector strat-
egy) resulted in genome editing and visible phenotypic changes in
nonclonal populations, but it was not possible to detect gene de-
letions at the sgRNA target sites. Gene mutations at the sgRNA
target sites were also undetected in clonal cell lines obtained by
limiting dilution of these TcPFR2 mutants, but Southern blot
analysis of these clones revealed dramatic changes suggesting large
deletions of TcPFR2. Deletions attributed to the function of a
microhomology-mediated end-joining double-strand break re-
pair system were previously detected only in an exogenous trans-
fected gene (that for GFP) (34). It is unclear why there is still a
wild-type sequence with the target site intact while the chromo-
somal TcPFR2 locus is clearly rearranged after expressing the
sgRNA that targets that locus and Cas9 alone. One possible expla-
nation is that the parasites canmaintain this wild-type sequence in
a location or structure that Cas9 cannot access. This copy of the
gene was not transcribed either, as observed by the decrease in
mRNA levels shown by Northern blot analysis.
The results obtained by transfection of sgRNA and Cas9 alone
are comparable to the downregulation of gene expression that can
be observed in T. brucei upon RNAi. In our case, deletion of the
TcPFR1, TcPFR2, and TcGP72 genes also allowed the detection of
FIG 5 Northern and Southern blot analyses of TcPRF2mutant parasites. Northern blot analysis (A) and densitometric quantitation (B) indicate that TcPFR2
mRNA is significantly downregulated in the subclones indicated while the two nearby genes (C) are not affected. The membranes were first hybridized with the
indicated TcPFR2, TcPPCS3, and TcDPaCS probes and then washed and hybridized to the alpha-tubulin gene used as a loading control. Northern blot analyses
with the TcPFR2 probe were performed with three different RNA preparations. Densitometric analysis was performed with ImageJ v1.48 software. Values were
normalized against the wild type (YWT). The GP72 CRISPR mutant was used as a control. (D) Southern blot analysis indicates that the TcPFR2 gene has been
rearranged. The genomic DNAs were extracted from the cell lines indicated and digested with EcoRI. After separated on 1% agarose gels and transfer to nylon
membranes, a TcPFR2 probe was used for hybridization (left). Arrows indicate changes in the pattern of bands observed in PFR2 CRISPR clones. A duplicate
membrane was hybridized to TcDPaCS (right).
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progressive loss of the proteins and the gradual appearance of the
final phenotypes, probably reflecting the slow turnover of the pro-
teins. As demonstrated by the silencing of PFR2 genes in L. major
(23), which are present in separate tandem arrays, this method
allows the silencing of families of genes containing homologous
sequences, an achievement that will allow the discovery of the
function of large gene families, such as those of trans-sialidases
(1,400 genes) and mucins (800 genes) (46). An important
advantage of this technique is that upon initial antibiotic selection
of epimastigotes, not all cells became deficient in the disrupted
gene. If the target gene in question is required for cell survival, this
partial selection results in only some epimastigotes showing a phe-
notypic change, i.e., flagellar detachment in the case of TcPFR1,
TcPFR2, and TcGP72, but they could also exhibit a growth defect
at the population level, suggesting an essential role of the gene.
PRF1 and PFR2 gene disruptions have been done before by
using T. brucei procyclic forms (18, 20, 21) and L. braziliensis
promastigotes (18, 22) to test different RNAi approaches and in-
vestigate their potential roles. In both cases, disruption mutants
were viable and loss of the paraflagellar rodwas observed, suggest-
ing that the assembly of this structure depends on the presence of
both PFR1 and PFR2. In the case of the procyclic form trypano-
somes, a blob of accumulated PFR components was present at the
tip of the flagellum of RNAi mutants but the flagellum remained
attached to the cell body (21). Double-knockout mutants of pro-
cyclic forms could not be obtained (24), while mutants obtained
by transfection of antisense PFR2 were not viable in case of the
bloodstream forms (21). We report here that partial disruption of
either PFR1 or PFR2 in T. cruzi epimastigotes with the CRISPR/
Cas9 system results in accumulation of PFR components at the tip
of the flagella and subsequent loss of the paraflagellar rod struc-
ture with flagellar detachment from the cell body. The cells appear
to lose the flagellum in the medium, and aflagellate epimastigote-
like cells appeared. Themutant cells showing flagellar detachment
have reduced cell motility and sink to the bottom of the culture
flasks. It has been reported previously that knockout of TcGP72
(28) (and RNAi ablation of the ortholog FLA1 in T. brucei procy-
clic forms [29]) also results in flagellar detachment from the cell
FIG 6 Phenotype analysis of TcPFR2 knockout cell line. (A) Schematic representation of the strategy used to generate a TcPFR2-KOmutant by CRISPR/Cas9-
induced homologous recombination. A double-stranded gDNA break was produced by Cas9 at nt40 of the TcPFR2 open reading frame. DNA was repaired
with a linear blasticidin S deaminase (BSD) cassette containing 100-bp homologous regions from the TcPFR2 locus (i). Arrows represent primers 13 and 14 (see
Table S1 in the supplemental material), which were used to verify gene disruption by PCR. The intact locus generates a PCR product of 376 bp (ii), while the
disrupted locus generates a fragment of 696 bp (iii). (B) PCR products obtained with gDNA from different cell lines were analyzed by electrophoresis on 1%
agarose gel. Lanes: L, 1-kb plus ladder; 1, wild type; 2, pTREX-n control cells; 3, Cas9/pTREX-n control cells; 4, scrambled sgRNA/Cas9/pTREX-n control cells;
5, TcPFR2-KO mutant cell line; 6, PCR negative control (H2O). (C) Western blot analysis of control and TcPFR2-KO epimastigotes. Total lysates (20 g/lane)
of wild-type (WT), scrambled control (Scr), and TcPFR2-KO epimastigotes were analyzed byWestern blotting withMAb L13D16. Anti--tubulin antibody was
used as a loading control. (D) Percentages of wild-type (WT) and TcPFR2-KO parasites exhibiting a detached flagellum, as visualized by light microscopy.
Observation of fixed parasites was performed in 20 fields with a 100 objective lens. (E) Growth curve of wild-type (blue) and TcPFR2-KO epimastigotes (red).
Results in panels D and E are expressed as mean values of three independent experiments the standard deviations. Comparison was performed by Student’s
t test with a significance level of P 0.05 (indicated by asterisks).
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body, and we confirmed these results with the CRISPR/Cas9
system.
In both T. cruzi and T. brucei, flagellar detachment affects the
motility of the parasites but does not affect the viability of the cells,
and this was confirmed here after the disruption of TcPFR2 by an
antibiotic-resistance marker. In addition, T. cruzi GP72 mutant
epimastigotes are able to differentiate into metacyclic stages and
infect tissue culture cells but produce no tissue culture-derived
trypomastigotes but only round formswith short flagella (microa-
mastigotes) or elongated forms with flagella emerging from the
middle of the cell (mesoamastigotes) that are deficient in infecting
mice and had lower viability in the insect vector (27, 47). It is also
interesting that disruption of the PFR assembly in T. brucei by
RNAi ablation of PFR-located calmodulin (48) results in loss of
the PFR structure and flagellar detachment. Our results support
the hypothesis that the assembly of the PFR is essential tomaintain
flagellar attachment to the cell body of trypanosomes.
In summary, the highly efficient gene disruption achieved by
CRISPR/Cas9-induced homologous recombination will greatly
improve our ability to perform genome editing in T. cruzi and, as
a consequence, facilitate the study of gene function in this parasite.
MATERIALS AND METHODS
Culturemethods. T. cruzi epimastigotes (Y strain) were grown at 28°C in
liver infusion tryptose (LIT) medium (49) supplemented with 10% heat-
inactivated fetal bovine serum (FBS). CRISPR mutant cell lines were
maintained in medium containing 250 g/ml G418 and/or 100 g/ml
blasticidin.We determined the growth of epimastigotes by measuring the
change in optical density at 600 nm in a Gilford spectrophotometer with a
starting culture of 4.5 106 epimastigotes or by counting cells in a Neu-
bauer chamber.
Chemicals and reagents. Taq polymerase, BenchMark Prestained
Protein Ladder, MagicMark XP Western Protein Standard, Alexa-
conjugated secondary antibodies, blasticidin S HCl, GENEART Site-
Directed Mutagenesis System and Topo TA Cloning kit were purchased
from Life Technologies (Grand Island, NY). G418 was from Calbiochem
(Darmstadt, Germany). Pierce BCA Protein Assay Reagent was from
Thermo Fisher Scientific Inc. (Rockford, IL). T4 DNA ligase was from
Promega (Madison, WI). Antitubulin MAb, anti-GFP polyclonal anti-
body, phleomycin and protease inhibitor cocktail (catalog number
p8840) were from Sigma (St. Louis, MO). IRDye-conjugated secondary
antibodies were from LI-COR Biosciences (Lincoln, NE). QIAprep Spin
Miniprep and Midiprep kits, QIAquick gel extraction kit, and MinElute
PCR purification kit were fromQiagen (Valencia, CA). The primers were
purchased from Integrated DNA Technologies (Coralville, IA). Antibiot-
ics and all other reagents of analytical grade were from Sigma (St. Louis,
MO).MAbL13D16 (44)was kindly provided by Philippe Bastin (Institute
Pasteur, Paris), MAbWIC29.26 (43) was a gift fromGeorge Cross (Rock-
efeller Institute, NY), and anti-T. cruzi flagellar calcium-binding protein
MAb (MAb FCaBP) was a gift from David Engman (Northwestern Uni-
versity, Evanston, IL). The pTREX-b and pMJ920 vectors were kindly
provided by Rick Tarleton andVasantMuralidharan (University of Geor-
gia, Athens, GA), respectively. Plasmid pUC_sgRNAwas custommade by
Blue Heron Biotech, LLC (Bothell, WA).
Molecular constructs. The CAS9-HA-2NLS-GFP fusion gene, con-
taining the S. pyogenes codon-optimized synthetic Cas9 sequence, the hu-
man influenza virus hemagglutinin (HA) tag, a twice-repeated sequence
of the SV40 nuclear localization signal (2NLS), and GFP, was amplified
from plasmid pMJ920 (Addgene) with primers containing XbaI andHin-
dIII restriction sites (primers 1 and 2; see Table S1 in the supplemental
material) to perform in-frame subcloning of the PCR product into the
pTREX-n (neomycin resistance) and pTREX-b (blasticidin resistance)
vectors (10). After confirming the sequence of the recombinant plasmid,
theCAS9-HA-2NLS-GFP fusion genewasmodified to remove a BamHI
restriction site without changing the predicted amino acid sequence, with
the GENEART site-directed mutagenesis system and primers 3 and 4 (see
Table S1 in the supplemental material). The final constructs were named
Cas9/pTREX-n and Cas9/pTREX-b, respectively (Fig. 1A). These recom-
binant plasmids were used to develop three different strategies for gene
silencing involving transfection of epimastigotes with one vector
(CRISPR-1V, Fig. 1B), two vectors (CRISPR-2V, Fig. 1C), and one vector
plus donor DNA for homology recombination (CRISPR-HR), respec-
tively (see Fig. S5 in the supplemental material). Chimeric sgRNA se-
quences to target genes TcPFR1 (TryTripDB accession no. TcCLB.
509617.20), TcPFR2 (TryTripDB accession no. TcCLB.511215.119), and
TcGP72 (GenBank accession no. AF507906) were PCR amplified from
plasmid pUC_sgRNA, containing the sgRNA backbone sequence (82 bp)
(50), with specific forward primers where protospacer regions (20- to
25-nt base-pairing region) were present (primers 5, 6, and 7; see Table S1
in the supplemental material) and the same reverse primer (primer 8; see
Table S1 in the supplemental material) for all of the sgRNAs amplified.
The presence of the protospacer-adjacent motif NGG (PAM, a motif re-
quired for Cas9 recognition of the target sequence) was verified in all
chosen protospacer regions. ProtoMatch v1.0, a script kindly provided by
Sebastián Lourido (31), was used to verify that the chosen protospacers do
not generate Cas9 off targeting on the T. cruzi genome. Primers 5 to 8,
designed to amplify sgRNAs, also contained a BamHI restriction site for
the individual cloning of these sequences into the Cas9/pTREX-n and
Cas/pTREX-b vectors, upstream of the HX1 trans-splicing signal (10).
The TcPFR1 and TcPFR2 sgRNAs were cloned by BamHI into the Cas9/
pTREX-b vector to generate the TcPFR1sgRNA/Cas9/pTREX-b and
TcPFR2sgRNA/Cas9/pTREX-b constructs (blasticidin resistant). TcGP72
sgRNA was cloned by BamHI into the Cas9/pTREX-n vector (neomycin
resistant) to generate the TcGP72sgRNA/Cas9/pTREX-n plasmid (all-in-
one vector strategy, CRISPR-1V; Fig. 1B), which was used to transfect
T. cruzi epimastigotes and generate green fluorescent mutant cell lines.
Alternatively, TcPFR1 and TcPFR2 sgRNA sequences were cloned by
BamHI into the tdTomato/pTREX-b vector to generate the
TcPFR1sgRNA/tdTomato/pTREX-b and TcPFR2sgRNA/tdTomato/
pTREX-b constructs. The tdTomato/pTREX-b plasmid was generated by
amplifying the tdTomato tag sequencewith primers 9 and 10 (see Table S1
in the supplemental material) and subcloning it into the pTREX-b vector
by using XbaI and HindIII restriction sites. For the two-vector strategy
(CRISPR-2V, Fig. 1C), the TcPFR3sgRNA/tdTomato/pTREX-b and
TcPFR2sgRNA/tdTomato/pTREX-b constructs were used together with
the Cas9/pTREX-n plasmid to transfect T. cruzi epimastigotes and gener-
ate double-resistant (neomycin and blasticidin) red and green fluorescent
cell lines. All of the molecular constructs generated in this study were
verified by sequencing.
Gene disruption by CRISPR-Cas9 with donor DNA. The TcPFR2
sgRNA sequence was cloned into the Cas9/pTREX-n vector by using the
BamHI site as described above and then used to cotransfect T. cruzi epi-
mastigotes with a linear donor DNA template to induce DNA repair by
homologous recombination (CRISPR-HR). This cassette was generated
by PCR with 120-bp ultramers (primers 11 and 12; see Table S1 in the
supplemental material) fromwhich 100 bp correspond to regions located
upstream of the start codon (forward primer) and downstream of the
Cas9 target site (reverse primer) of theTcPFR2 gene and 20 bp for anneal-
ing on the blasticidin-S deaminase gene (Bsd) on the pTREX-b vector,
which was used as a PCR template. Epimastigotes cotransfected with
TcPFR2sgRNA/Cas9/pTREX-n and a blasticidin resistance cassette were
cultured with G418 and blasticidin for selection of double-resistant para-
sites. Primers 13 and 14 (see Table S1 in the supplemental material) were
used in a PCR assay to verify disruption of the TcPFR2 gene by the blas-
ticidin resistance cassette. For a detailed protocol for gene disruption in
T. cruzi by CRISPR/Cas9-mediated homologous recombination, see Sup-
plemental Methods S1 in the supplemental material.
Cell transfections. T. cruzi Y strain epimastigotes (4  107 cells, at
room temperature [RT], suspended in phosphate-buffered saline [PBS],
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pH 7.4) were transfected in ice-cold CytoMix (25 mM HEPES, 120 mM
KCl, 0.15 mMCaCl2, 10 mMK2HPO4, 2 mM EGTA, 5 mMMgCl2, 0.5%
glucose, 100 g/ml bovine serum albumin [BSA], 1 mM hypoxanthine
[pH 7.6]) containing 25 g of each plasmid construct or donor DNA in
4-mm electroporation cuvettes with three pulses (1,500 V, 25 F) deliv-
ered by a Gene Pulser II (Bio-Rad). Stable cell lines were established and
maintained under drug selection (250 g/ml G418 and/or 100 g/ml
blasticidin). Until stable cell lines were obtained, LIT medium was sup-
plemented with 20% heat-inactivated FBS. Transfectant cell lines were
sorted by either green or green/red fluorescence before clonal populations
were obtained by serial dilutions in 96-well plates with conditioned me-
dium (40% fresh LIT, 40% conditioned LIT, 20% heat-inactivated FBS)
supplemented with selective drugs.
FACS. After selection of transfectant cell lines, mixed populations of
epimastigotes were sorted at the CTEGD Flow Cytometry Core Facility
(University of Georgia, Athens, GA)with an S3 sorter (Bio-Rad,Hercules,
CA). Green fluorescence was excited with a 488-nm laser and read
through a 525/30-nmband-pass filter in log. Red fluorescence was excited
with a 561-nm laser and read through a 586/25-nm laser in log. Acquisi-
tionwas triggered on forward scatter (FSC), and light scatter was collected
on log (log FSC versus log side scatter).
Sequence analysis. Genomic DNA was extracted from parental and
mutant cell lines and used as the template to amplify fragments of 200 to
1,500 bp containing the protospacer regions chosen for Cas9 targeting of
the TcPFR1, TcPFR2, and TcGP72 genes. PCR products were cloned into
the pCR2.1-TOPO vector, and several clones were sequenced with uni-
versal primersM13 reverse and T7 promoter. Sequences were analyzed to
verify the presence of mutations with DNAMAN software (version 7.212;
Lynnon Corp., Quebec, Canada).
Western blot analysis. Parental and mutant cell lines were harvested
separately. Parasites were washed twice in PBS and resuspended in radio-
immunoprecipitation assay buffer (150 mM NaCl, 20 mM Tris-HCl
[pH 7.5], 1 mM EDTA, 1% SDS, 0.1% Triton X-100) plus a mammalian
cell protease inhibitor mixture (Sigma P8340, diluted 1:250), 1 mM
EDTA, 1-mM phenylmethylsulfonyl fluoride, 2.5 mM tosyl phenylalanyl
chloromethyl ketone (TPCK), 100 M N-(trans-epoxysuccinyl)-L-
leucine 4-guanidinobutylamide (E64), and Benzonase nuclease (25 U/ml
of culture). The cells were then incubated for 1 h on ice. Cell lysis was
verified under a light microscope, and protein concentration was deter-
mined by a bicinchoninic acid protein assay (Pierce). Twentymicrograms
of protein from each cell lysate wasmixedwith 4 Laemmli sample buffer
and analyzed by SDS-PAGE in 10% gels. Separated proteins were trans-
ferred onto nitrocellulose membranes (Bio-Rad) with a Bio-Rad Trans-
blot apparatus.Membranes were blocked with 5%nonfat dried skimmilk
in PBST (PBS containing 0.1% [vol/vol] Tween 20) overnight at 4°C.
Next, blots were incubated for 1 h at RT with a primary antibody, i.e.,
MAb L13D16 (1:50 dilution) (44), MAb WIC29.26 (1:1,000) (43), an
antitubulin MAb (1:50,000), or an anti-GFP polyclonal antibody (1:
1,000). After three washes with PBST, blots were incubated with the ap-
propriate secondary antibody for 1 h at RT in the dark, i.e., IRDye 680RD-
conjugated goat anti-rabbit IgG (1:15,000) or IRDye 800CW-conjugated
goat anti-mouse IgG (1:15,000). Membranes were washed three times
with PBST, and Western blot images were obtained and processed with
the Odyssey infrared imaging system (LI-COR Biosciences).
Northern and Southern blot analyses. For Northern blot analysis,
total RNA was isolated from epimastigotes with TRI reagent. RNA was
subjected to electrophoreses in 1% agarose gels containing 2.2 M formal-
dehyde, 20mMmorpholinepropanesulfonic acid (MOPS; pH 7.0), 1mM
EDTA, and 8 mM sodium acetate; transferred to nylon membranes; and
hybridized with radiolabeled probes containing 500 bp of the genes ob-
tained by PCR. The alpha-tubulin gene was used as a loading control. The
results were quantified by PhosphorImager analyses. DNA probes were
labeled with [-32P]dCTP (Perkin-Elmer) with random hexanucleotide
primers and the Klenow fragment of DNA polymerase (Prim-a-Gene La-
beling System). For Southern blot analysis, total genomic DNA was iso-
lated from epimastigotes by phenol-chloroform extraction, digested with
EcoRI, separated on a 1% agarose gel, and transferred to nylon mem-
branes. The blot was probed with [-32P]dCTP-labeled TcPFR2,
TcCLB.508837.180 (DNA polymerase catalytic subunit, putative), or
TcCLB.508839.30 (trafficking protein particle complex subunit 3, puta-
tive).
Immunofluorescence microscopy. Epimastigotes were washed with
PBS and fixed with 4% paraformaldehyde in PBS for 1 h on ice. Cells were
allowed to adhere to poly-L-lysine-coated coverslips and then permeabil-
ized for 5 min with 0.1% Triton X-100. Permeabilized cells were incu-
bated for 1 h at RT with 100 mMNH4Cl in PBS and blocked overnight at
4°C with 3% BSA in PBS (pH 8.0). Cells were incubated with a primary
antibody (MAb FCaBP [1:10] or MAb WIC29.26 [1:100]) for 1 h at RT.
Excess primary antibody was removed from the cells with three washes
with 1% BSA in PBS (pH 8.0), and then cells were incubated for 1 h at RT
in the dark with an Alexa Fluor 546-conjugated goat anti-mouse second-
ary antibody (1:1,500). Following incubation with the secondary antibody,
cellswerewashedandmountedonslides.DAPI (5g/ml)was included in the
mounting medium to stain DNA. Secondary-antibody controls were per-
formed as described above but in the absence of a primary antibody. Differ-
ential interference contrast and fluorescence optical images were captured
under nonsaturating conditions with an Olympus IX-71 inverted fluores-
cence microscope with a Photometrix CoolSnapHQ charge-coupled device
camera driven by DeltaVision software (Applied Precision, Issaquah, WA).
Deconvolution was done as described before (13).
Scanning EM and TEM. Epimastigotes were processed for TEM at the
Electron Microscopy Facility of the Department of Pathology, College of
Veterinary Medicine, University of Georgia, Athens, GA. TEM images
were obtained with a JEM-1210 transmission electron microscope (JEOL
United States Inc., Peabody, MA) equipped with an XR41C bottom-
mount CCD camera from Advanced Microscopy Techniques, Corp.,
Woburn, MA. Parasites for scanning EMwere processed and viewed with
a Zeiss 1450EP scanning electron microscope at the Center for Advanced
Ultrastructural Research, University of Georgia.
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